Vimta Labs Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 24 Aug 2026 | Healthcare Services | Market Cap: ₹2.8K Cr
Vimta Labs aims to maintain a strong CAGR similar to the last 5-7 years, targeting INR 500 crores in annualized revenue by FY27. Vimta Labs targets maintaining a strong CAGR seen over the last 5-7 years, aiming for INR 500 crores annual revenue run rate by FY27 despite some recent headwinds.
From Vimta Labs Ltd's Q4 FY26 earnings-call transcript · updated 24 Aug 2026.
Price
₹616
Market Cap
₹2.8K Cr
P/E Ratio
34.8
How does Vimta Labs Ltd rank in Healthcare Services?
Compare Vimta Labs Ltd against every Healthcare Services company this quarter on revenue, margins and earnings-call signals.
Vimta Labs Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹109 Cr, net profit ₹21 Cr.
Full financials →📊 Revenue & Sales Performance
- →Vimta Labs aims to maintain a strong CAGR similar to the last 5-7 years, targeting INR 500 crores in annualized revenue by FY27.
- →Growth drivers include pharmaceuticals, food testing, and electronics, with good visibility and expanding markets.
- →The company anticipates continued robust demand, especially in pharma analytical and biologics contract research.
- →Electronics and electrical testing are expected to gain momentum post fixing leadership challenges.
- →Biologics contract research is set to commence in FY27, with efforts underway to onboard clients.
- →Expansion facilities are planned to support growth for the next 4-5 years.
- →Despite geopolitical and economic uncertainties, Vimta remains hopeful to sustain and grow revenue momentum.
- →Focus on international market expansion and increasing share in overseas pharma and food testing contracts.
- →Growth seen in FDA-compliant pharma testing and food testing helped Q4 revenue achieve all-time highs.
📈 Profitability & Margins
- →Vimta Labs targets maintaining a strong CAGR seen over the last 5-7 years, aiming for INR 500 crores annual revenue run rate by FY27 despite some recent headwinds.
- →EBITDA margins are expected to stay above 35%, with possible minor fluctuations of 1-2% due to cost pressures but generally stable.
- →The company aims to sustain revenue momentum (INR 120-130 crores quarterly) driven by pharma and food testing divisions.
- →Biologics contract research, starting FY27, is expected to build traction gradually without significant immediate revenue impact.
- →The new US subsidiary will support customer proximity, potentially aiding future revenue growth.
- →Vimta remains net debt-free with INR 650 million cash, with no immediate plans for fundraising, ensuring capital for growth.
- →Long-term growth is supported by increasing outsourcing trends in pharma, food, and electronics sectors, alongside rising R&D and regulatory demands.
🏗️ Capital Expenditure Plans
- →Currently, there is no firm or concrete plan for raising funds through methods like rights issues for ramping up the capex, as per Harita Vasireddi (Page 13).
- →The company has recently moved into new facilities that are designed to support growth for the next 4-5 years (Page 11).
- →Utilization of the new facility is expected to pick up gradually over this year and the next (Page 11).
- →There are no specific plans mentioned for acquisitions or capacity expansions at present, but management will announce if something materializes (Page 12).
- →The newly set-up US subsidiary aims to be closer to customers rather than for tariff benefits or significant investments (Page 11).
- →The entry into biologics contract research and development services is a strategic milestone; investments in people, infrastructure, and equipment have already been made to support this vertical (Pages 4, 12).
💰 Fundraising & Capital Structure
- →Currently, there is no plan to raise funds through rights issue or other equity methods.
- →The company has cash of INR 650 million (as of Q4 FY26), and management feels no immediate need for fundraising via such methods.
- →No firm plans on debt or other capital raising methods have been disclosed.
- →Management will share any updates on fundraising if and when such plans materialize.
- →The company prefers to maintain a net debt-free balance sheet with sufficient cash reserves for uncertainties.
📋 Order Book & Pipeline
- →Vimta Labs has reported good inquiries and traction for new projects.
- →They have promising prospects from Europe, India, and some from the US.
- →Finalizations for product and modality of these projects are underway.
- →Some biologics contract research projects are under discussion, with hopes of materializing soon.
- →While no concrete plans for acquisitions or major expansions are firmed up, the company is exploring potential opportunities.
- →Management is confident about maintaining revenue momentum with an aim to keep quarterly revenues around INR120-130 crores.
- →The new facility's utilization is expected to ramp up gradually over the next few years to support growth.
- →Overall business visibility is good, with steady pipelines across pharmaceutical, food, electronics, and biologics segments.
Key Metrics
Continue your research
What Vimta Labs's management said in earlier quarters
Others in Healthcare Services this season
- Apollo Hospitals Enterprise Ltd (Q4 FY26)
30% growth currently driven by top 5 markets; expansion planned into new markets. Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q4 FY26 earnings…
- Health X Platform (Q4 FY26)
Northeast operations growing 50%+ year-on-year and Northern India 25–30%, with plans for 5–7% market share in 2-3 years (Page 10). Key concall takeaways from…
- Park Medi World (Q4 FY26)
Total planned capex for the next two years is around INR 500 crores. Key concall takeaways from Park Medi World's Q4 FY26 earnings call — and how it ranks…
- Vijaya Diagnostic Centre Ltd (Q4 FY26)
Hyderabad to sustain double-digit growth (~20%) in near term, with additional spokes opening and market share gains. Key concall takeaways from Vijaya…
Frequently Asked Questions
What were Vimta Labs Ltd Q4 FY26 results?
Vimta Labs aims to maintain a strong CAGR similar to the last 5-7 years, targeting INR 500 crores in annualized revenue by FY27. Vimta Labs targets maintaining a strong CAGR seen over the last 5-7 years, aiming for INR 500 crores annual revenue run rate by FY27 despite some recent headwinds.
What is Vimta Labs Ltd share price analysis?
Vimta Labs Ltd currently shows a neutral. The stock trades at a P/E of 34.8 with a market cap of ₹2,814 Cr. Investors should review the full earnings analysis for detailed insights.
Is Vimta Labs Ltd planning capital expenditure?
Currently, there is no firm or concrete plan for raising funds through methods like rights issues for ramping up the capex, as per Harita Vasireddi (Page 13).
Keep Vimta Labs Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.